Ghassan K. Abou-Alfa, MD, on Integral Developments Leading to Phase 3 HIMALAYA Trial in Hepatocellular Carcinoma


Ghassan K. Abou-Alfa, MD, detailed the evolution of treatment options for unresectable hepatocellular carcinoma prior to the phase 3 HIMALAYA study and the reasons for launching the trial.

CancerNetwork® spoke with Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Comprehensive Cancer Center, at the 2022 Gastrointestinal Cancer Symposium, about important developments leading to the examination of tremelimumab plus durvalumab (Imfinzi) compared with durvalumab alone for unresectable hepatocellular carcinoma in the phase 3 HIMALAYA study (NCT03298451).


Interestingly, it took a long while to get to this point [of presenting research at the 2022 Gastrointestinal Cancers Symposium]. If anything, I’m humbled to say that I started in the field before any therapy was available. We started with sorafenib [Nexavar], we evolved to [using another tyrosine kinase inhibitor] lenvatinib [Lenvima] in first-line therapy. There’s no question we all were interested in immunotherapy. We were looking forward to that because of the real effects that we anticipated in the setting of hepatocellular carcinoma [HCC] with the hyperimmune effects. Interestingly, the single-agent anti–PD-1 or anti–PD-L1 did not fare that well. If anything, it clearly started evolving the need for certain priming for that entity of the anti–PD-1, anti–PD-L1 effect. We have seen it with VGF or with FGF. HIMALAYA has completely evolved. The anti–CTLA-4 that comes into play as an important, powerful booster extract that comes all the way from the top of the chain in the lymph node itself to further enhance anti–PD-1, anti–PD-L1 activity. This led to the further evaluation of the HIMALAYA study.


Abou-Alfa G, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol. 2022;40(suppl 4):379. doi: 10.1200/JCO.2022.40.4_suppl.379

Related Videos
An expert from the University of California, Los Angeles suggests that the NALIRIFOX may be a beneficial treatment for patients with pancreatic ductal adenocarcinoma.
Patients with metastatic pancreatic ductal adenocarcinoma who receive NALIRIFOX tend to have more gastrointestinal toxicity while nab-paclitaxel/gemcitabine results in more cytopenias, according to an expert from University of California, Los Angeles.
An expert from the University of California, Los Angeles described the purpose and design of the phase 3 NAPOLI-3 study, assessing NALIRIFOX in metastatic pancreatic ductal adenocarcinoma.
Adding radiation to sorafenib elicited a survival improvement in a group of patients with hepatocellular carcinoma, a type of liver cancer.
An expert from the Mayo Clinic discusses how findings from the ongoing phase 3 MOUNTAINEER trial may enable access to tucatinib, trastuzumab, and chemotherapy in earlier lines of treatment for patients with HER2-positive metastatic colorectal cancer.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
The combination of tremelimumab plus durvalumab improved survival for patients with unresectable hepatocellular carcinoma in the phase 3 HIMALAYA trial.
Related Content